World Investment Advisors Has $1.87 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

World Investment Advisors raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 55.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 21,706 shares of the company’s stock after purchasing an additional 7,781 shares during the quarter. World Investment Advisors’ holdings in Novo Nordisk A/S were worth $1,867,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in NVO. GQG Partners LLC raised its stake in Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after buying an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Folketrygdfondet lifted its stake in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock valued at $765,917,000 after purchasing an additional 40,313 shares during the period. Sustainable Growth Advisers LP boosted its position in shares of Novo Nordisk A/S by 23.6% during the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after purchasing an additional 1,021,498 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $404,910,000. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on NVO shares. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 6.7 %

NYSE:NVO opened at $62.58 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $62.37 and a one year high of $148.15. The company has a market cap of $280.84 billion, a PE ratio of 19.02, a PEG ratio of 0.90 and a beta of 0.61. The firm has a 50-day moving average of $80.85 and a 200-day moving average of $96.75.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.